Background. Plasma nitric oxide (NO) levels have been found to be high in haemodialysis (HD) patients, especially in those prone to hypotension in dialysis. The aim of the study was to prevent dialysis hypotension episodes by i.v. administration of methylene blue (MB), an inhibitor of NO activity anduor production. Methods. MB was given i.v. in 18 stable HD patients with hypotensive episodes during almost every dialysis, in 18 HD patients without hypotension during dialyses, and in ®ve healthy controls. MB was given as a bolus of 1 mgukg bodyweight followed by a constant infusion of 0.1 mgukg bodyweight lasting 210 min until the end of the dialysis session and only as a bolus on a non-dialysis day. Systolic and diastolic blood pressures (BP) were measured at 10-min intervals during HD sessions with or without MB and on a non-dialysis day with MB. Results. In hypotension-prone patients, MB completely prevented the hypotension during dialysis and increased both systolic and diastolic BP on nondialysis days. In normotensive patients, MB increased BP during the ®rst hour of dialysis and for 90 min on the non-dialysis day. The BP in the healthy controls remained unchanged. Plasma and platelet NO 2 qNO 3 (stable metabolites of NO) levels were determined. The NO 2 qNO 3 generation rate in the ®rst postdialysis day was calculated. The plasma and platelet NO 2 qNO 3 were higher in the hypotensive group than in the normotensive dialysis group. The generation rate of nitrates was higher (P-0.01) in the hypotensive group (1.21"0.13 mmolumin and 0.74"0.16 after MB) than in the normotensive patients (0.61"0.11 mmolu min and 0.27"0.14 after MB). No side-effects were recorded.
Introduction
Dialysis hypotension remains one of the most frequent intradialytic complications, although important improvements have been made in the dialysis techniques. The incidence of symptomatic hypotensive episodes during the haemodialysis (HD) sessions is high in the patients who have low or normal blood pressure and in those with large interdialytic weight gain w1,2x. The¯uid removal during dialysis with its haemodynamic consequences (hypovolaemia, fall in circulating ®lling pressure and in cardiac output) is considered to be an important cause of these symptomatic hypotensive episodes w3x. However, in many patients without hypovolaemia, moderate or severe hypotensive episodes occur during HD and are reasonably explained by high venous capacity for the normal blood volume anduor an inappropriately low peripheral arterial resistance w4x. Beasley and Brenner w5x suggested that nitric oxide (NO), a very potent endogenous vasodilator, may be blamed for these hypotensive events.
It was found that NO production may increase signi®cantly during HD w6±20x. Increased NO generation between and during dialysis sessions may result in signi®cant and rapid vasodilatation, i.e. hypotension.
The aim of the present study was the prevention of the intradialytic hypotensive episodes by the intravenous administration of methylene blue (MB), an agent known to inhibit the vasodilatory effect of NO w21,22x.
Subjects and methods

Subjects
The study protocol was approved by the Helsinki Committee and patients and volunteers all gave their informed consent.
Twenty nine patients (aged 29±69 years) with end-stage renal failure on maintenance HD participated in the study. The patients had been on dialysis for 3±21 years.
Fourteen had chronic glomerulonephritis, four polycystic kidney disease, two NIDDM, one analgesic nephropathy, and eight different tubulointerstitial nephropathies. Although none had severe congestive heart failure, class 1 or 2 NYHA CHF patients were not excluded from the study. Patients with adrenal insuf®ciency, chronic salt anduor volume depletion, pericardial effusion or constriction, or infections were not included. None of them received antihypertensive drugs or any other agents known to in¯uence the blood pressure.
Patients with active coronary heart disease (as assessed by clinical symptoms, ECG and myocardial functionÐ perfusion as measured by Tc-MIBI imaging) or on nitrate therapy were also excluded because of the potential reduction in coronary blood¯ow due to NO inhibition w23x.
Eighteen of these patients (group 1, age 56"9 years, on dialysis for 3±11 years) had blood pressures ranging between 90 and 110u65±70 mmHg before dialysis and had intradialytic hypotensive episodes in at least four of the previous six HD sessions not responsive to a¯uid challenge of 250 ml normal saline.
A dialysis hypotension episode was de®ned as a sudden reduction in systolic blood pressure of 20 mmHg or more in the ®rst 2 h of dialysis. We chose this de®nition in order to minimize the effect of the¯uid removal on the blood pressure, known to be more prominent in the second half of dialysis w24x.
HD patients had a pre-set¯uid removal of 1000 ml in the ®rst 2 h of HD with or without MB. The mean weight gain was similar before the two study dialysis sessions with or without methylene blue; 1.9"0.7 and 2.05"0.65 kg respectively.
Various procedures had been used before the study in order to alleviate the hypotension and the symptoms: sequential ultra®ltration and dialysis, high (150 mEqul) initial Na concentration in the dialysate with progressive reduction of the concentration during dialysis, dialysate cooling, and volume administration (hypertonic saline solutions). All these had partial and inconsistent effect on the prevention of the hypotensive episodes. This group was considered as dialysis hypotension-prone patients.
The remaining 11 dialysis patients (group 2, age 54"7 years, 3±21 years on dialysis) were normotensive (blood pressure 135±140u80±85 mmHg) and had very rare symptomatic hypotensive episodes (less than one in 2 months). The mean weight gain was similar before the two study dialysis sessions with or without MB (2.07"0.6 and 2.12"0.6 kg respectively). Five healthy volunteers (group 3 age 49"10 years) participated in the study.
All patients received erythropoietin treatment. Patients and volunteers had no G6PD de®ciency. MB is reported to produce haemolysis in these subjects w25x.
The dialysis ef®ciency, documented by KtuV, was 1.35"0.70 in the normotensive group and 1.27"0.50 in the hypotensive group. The dialysers used were Fresenius F6 or Sure Flux 1.3 m 2 hollow-®bre dialysers. Blood¯ow ranged from 250 to 350 mlumin and was the same for the patients throughout the study. Bicarbonate (35 mEqul) dialysis solution with a Na concentraton of 140 mEqul was used. The desired ultra®ltration necessary to achieve the target weight reduction was divided equally over the entire dialysis session.
MB administration
All HD patients underwent three tests, two during two consecutive HD sessions (one dialysis without MB and one with MB administration), and the third test on a non-dialysis day. The normal volunteers underwent one test. All tests lasted 240 min. MB was given as an i.v. bolus (1 mgukg bw) over 5±6 min, in 30 ml normal saline on the non-dialysis day and in the normal volunteers.
The bolus of MB during the dialysis was given immediately before HD in a peripheral vein and not through the ®stula, and was followed by a continuous infusion of 0.1 mgukg bw in a total of 200 ml normal saline solution throughout the entire dialysis session. Each HD lasted 210 min followed by a 30-min post-dialysis observation period.
The blood pressure and heart rate were measured by an automatic recording device every 10 min during all tests. ECG was recorded before and after dialysis and monitored during dialysis.
Blood samples were drawn in all tests before, at 105 min, at 210 min (end of dialysis) and at 240 min (end of the test).
Laboratory determinations
Haemoglobin, haematocrit, reticulocytes, LDH, bilirubin, and methaemoglobin were determined by standard laboratory methods.
Nitrite (NO 2 ) and nitrate (NO 3 ), the stable metabolites of NO, were measured as previously described w26x. Brie¯y, after reduction of NO 3 to NO 2 with nitrate reductase (prepared from E. coli in our laboratory) the NO 2 was determined spectrophotometrically with Griess reaction. The NO 2 qNO 3 generation rate was calculated from the values obtained at the end of dialysis and those determined after 24 h and expressed in mmolumin according to the formula Gs$(V2 3 C2)À(V3 3 C3)%u1440 in which V2 volume of distribution of NO 2 qNO 3 (as for urea), C2 is the NO 2 qNO 3 plasma concentration immediately after dialysis, V3 3 C3 is the volume of distribution and NO 2 qNO 3 plasma concentration after 24 h w27x.
Statistics
Mean"SD, two-way analysis of variance with repeated measurements, Student's t-test was used to assess statistical signi®cance. P-0.05 was considered signi®cant.
Results
The effect of MB on blood pressure (Figures 1 and 2 ). The administration of MB to healthy volunteers did not change the blood pressure. In the normotensive dialysis patients, who had no dialysis hypotension, MB administration resulted in signi®cantly higher systolic and diastolic blood pressure compared with the values during a dialysis session without MB (P-0.001 by two-way analysis of variance with repeated measurements). The highest values after MB were measured during the ®rst 90 min of dialysis.
In the dialysis patients with hypotensive episodes during the HD session without MB, both systolic and diastolic pressure decreased signi®cantly after the ®rst hour of dialysis.
In the same group of patients, the decrease in blood pressure was prevented during the dialysis session when MB was administered. Both systolic and diastolic curves during the dialysis with MB were very signi®cantly different from those of the dialysis session without MB.
MB administration on a non-dialysis day resulted in an increase in both systolic and diastolic blood pressure in all dialysis patients for at least 180 min.
The changes in heart rate did not attain statistical signi®cance in any group of dialysis patients and volunteers during the dialysis sessions or on a non-dialysis day.
Side-effects
Three patients complained of slight pain at the injection site during the MB administration. In four dialysis patients, a bluish discoloration of lips was observed, without any complaint. No other side-effects were recorded. No ECG changes were recorded. No signs of haemolysis anduor methaemoglobinaemia were found.
After the end of dialysis and termination of the MB administration, the blood pressure decreased to the predialysis values and the patients remained asymptomatic.
Plasma nitrates (Table 1)
The patients with dialysis hypotension had higher nitrates levels than those with normal blood pressure but this difference did not reach statistical signi®cance. The nitrates levels decreased signi®cantly during the dialysis in both groups with or without MB treatment. The nitrates generation rate in the ®rst post-dialysis day was higher in the dialysis-hypotensive patients (1.21"0.13 mmolumin) compared to the normal blood-pressure patients (0.61"0.11 mmolumin) P-0.01. Furthermore, the nitrites generation rate in the ®rst post-dialysis day following a HD session with MB was higher in the dialysis-hypotensive patients compared to the normotensive patients (0.74"0.16 vs 0.27"0.14 mmolumin, P-0.01). Fig. 1 . Changes in systolic and diastolic blood pressure in dialysis patients treated or untreated with MB during a HD session. Average blood pressure of all the groups measured every 10 min is shown. A, hypotension-prone dialysis patients; B, normotensive dialysis patients. Continuous line, HD with MB; interrupted line, HD without MB. In both HD patients groups, the administration of MB resulted in signi®cantly higher blood pressures compared with those measured during a dialysis performed without MB (P-0.005 at least, by two-way analysis of variance with repeated measurements). 
Discussion
The major ®nding of the present study is the prevention of intradialytic hypotension by the continuous i.v. administration of MB. MB is known to block cGMP w21,22x, thus inhibiting the action of the NO resulting from the increased NO synthase (NOS) activity. It also has the ability to scavenge NO w28x, as well as to inhibit NO synthesis w29x. MB has been given for many years for clinical purposes without serious side-effects w25,30,31x. The previously described side-effects of MB include: haemolysis and skin eruption due to photosensitivity nitric oxide, one of the most potent endogenously-produced vasodilator molecules, seems to be a very good candidate to cause intradialytic hypotension. Several reports suggest that NO production is enhanced in HD patients w6±20x. The exposure of healthy blood to HD membranes, mainly to cuprophane, markedly enhanced the expression of mRNA encoding for inducible NOS by a line of murine endothelial cells w6,18x.
In all probability the release of cytokines like IL-1b and TNFa by activated mononuclear cells triggers the activation of NOS. Noris et al. w9x found that platelets of uraemic patients produce increased amounts of NO, leading to hypotension during dialysis. It has also been suggested w32x that heparin promotes NO production by human vascular endothelial cells in culture, but in an in vivo study w8x in dialysis patients by the same group w7x it was found that heparin was not involved in NO production. These authors also found that NO production increased in patients who had a hypotensive episode during dialysis but not in those who remained normotensive during dialysis. NO production was negatively correlated with the mean blood pressure after dialysis.
However, the haemodynamic role of NO is still not clear because of the increased plasma concentration of inhibitors of NO like ADMA in end-stage renal disease w11,19,20,33x. These substances are dialysable, so the ®nal effect of the end-stage uraemic plasma on NOS activity derives from the balance between inhibitors and activators. In a previous work (unpublished) we found signi®cantly higher levels of NO 2 and NO 3 in the plasma of HD patients as compared with normal controls. These levels decreased progressively during dialysis, indicating that they were probably cleared.
Recently, direct NO measurements of the blood of dialysis patients by a NO-selective electrode con®rmed the increased NO production during HD w8,13x. Calculation of the rate of nitrates generation showed that dialysis enhanced nitrates production. However, although the plasma NO 2 and NO 3 levels must be taken with some caution for establishing a true generation rate, our results on the ®rst post-dialysis 24 h generation rate strengthen our ®ndings.
NO may lower the blood pressure not only by its powerful vasodilatory effect or by opposing vasoconstriction, but also by its negative inotropic effect w34,35x. The MB administration in the dose we used had no effect on blood pressure and heart rate in normal controls. This was in contrast with the effect of another systemic NO inhibitor L-NMMA, given to healthy individuals w36x. However, in the dialysis patients, MB given on a non-dialysis day increased blood pressure in both of the studied groups. This may be explained by the lower total peripheral resistance due to an enhanced NO production in the hypotension-prone patients.
Our study has some limitations. Only patients without coronary heart disease were included, because of the possible implications of the systemic NOS inhibition on the coronary vascular bed w23x. In our patients, there were no signs or symptoms of cardiac ischaemia due to MB administration. Only a single dose of MB was used.
No pharmacokinetic data on MB were obtained during HD, and the decision to choose a continuous infusion of the substance during dialysis was empirical. Recently a method for MB quantitation was described in cat®sh tissue w37x.
In a very recent publication, MB was given i.v. to ®ve neonates with refractory neonatal hypotension in the same dose as used by us, with very good results w38x.
MB had no signi®cant effect of the blood levels of nitrates. The nitrate levels before dialysis were not different statistically in the patients with hypotension and those with normal blood pressure, as Yokokawa et al. w7x also found. However, in their study NO 2 qNO 3 levels measured after 4 h of dialysis did not change in the normotensive subjects, but were greatly increased in their hypotensive patients, while these levels decreased in our patients, as reported also other publications w8x. Yokokawa also found a decrease in cGMP blood levels instead of the expected elevation due to NO activity. We did not ®nd signi®cant differences in NO 2 qNO 3 levels measured during dialysis between the groups. Mean"SD; NO 2 qNO 3 in mmolul; HD, haemodialysis; ÀHD, non-HD day; MB, methylene blue; *P-0.05 (at least vs the predialysis respective values).
However, the nitrates generation rate values in the ®rst 24 h after a dialysis session, were signi®cantly higher in the hypotensive patients with or without MB treatment. After MB, the generation rate decreased in both groups. We found, as did Noris et al. w9,10x, that dialysis patients produced more NO than healthy controls. Furthermore, the dialysis hypotension-prone patients have higher NO compared with the normotensive group. This high generation rate of nitrates and the effect of MB in this group of dialysis patients emphasized the role of NO in the pathogenesis of dialysis hypotension.
In conclusion, MB may be an ef®cient therapeutic agent for the prevention of dialysis hypotension. Since the completion of the study, nine hypotension-prone dialysis patients have received MB during HD once weekly at least six times, with effective prevention of dialysis hypotensive episodes, and with no side-effects. However, a long-term study is necessary to assess the safety of chronic MB administration in HD patients.
